Skye Bioscience, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – SKYE

Core Viewpoint - Skye Bioscience, Inc. is facing a class action lawsuit for securities law violations, specifically for making false and misleading statements regarding the efficacy of its product, nimacimab [1][2]. Summary by Sections Class Action Details - The class period for the lawsuit is from November 4, 2024, to October 3, 2025, with a deadline for lead plaintiff appointments set for January 16, 2026 [2]. - The complaint alleges that Skye's public statements were materially misleading, as the company failed to demonstrate the efficacy of nimacimab as previously claimed [2]. Shareholder Participation - Shareholders who purchased shares during the specified class period are encouraged to contact the DJS Law Group to participate in the lawsuit [3]. - There is no cost or obligation for shareholders to enroll in the case, and they will receive updates through a portfolio monitoring software [3]. Legal Representation - DJS Law Group specializes in securities class actions and corporate governance litigation, representing large hedge funds and alternative asset managers [4].